Lower Medication Requirement Helps Depression Patients Obtain Treatment SoonerMALVERN, Pa., May 26, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM),…
Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with…
— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results…
Lowest satisfaction among medication users, highest for users of non-drug solution TMS Therapy NeuroStar Depression Barometer Infographic FocalData survey results…
-Appointment expected to aid advancement of Theriva’s discovery program and strengthen collaboration with the Institut Catala d’Oncologia (ICO) and the…
BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…
PURCHASE, N.Y., May 23, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its…
Submission based on data from the pivotal international Phase III CONTENT clinical program, also recently published in European Urology1CONTENT showed that…
BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…
The Company is recognized for its commitment to employees’ well-beingMALVERN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:…